News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
670,782 Results
Type
Article (49418)
Company Profile (211)
Press Release (621127)
Multimedia
Podcasts (149)
Webinars (23)
Section
Business (183552)
Career Advice (2604)
Deals (33113)
Drug Delivery (155)
Drug Development (81046)
Employer Resources (152)
FDA (15579)
Job Trends (14372)
News (321695)
Policy (32345)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2743)
Academic (1)
Accelerated approval (45)
Adcomms (36)
Allergies (166)
Alliances (47018)
ALS (204)
Alzheimer's disease (1814)
Antibody-drug conjugate (ADC) (442)
Approvals (15873)
Artificial intelligence (651)
Autoimmune disease (248)
Automation (54)
Bankruptcy (342)
Best Places to Work (10976)
BIOSECURE Act (19)
Biosimilars (224)
Biotechnology (110)
Bladder cancer (180)
Brain cancer (69)
Breast cancer (702)
Cancer (5602)
Cardiovascular disease (489)
Career advice (2207)
Career pathing (46)
CAR-T (310)
CDC (60)
Celiac Disease (1)
Cell therapy (817)
Cervical cancer (38)
Clinical research (70012)
Collaboration (1960)
Company closure (6)
Compensation (923)
Complete response letters (94)
COVID-19 (2784)
CRISPR (102)
C-suite (1107)
Cystic fibrosis (141)
Data (7353)
Decentralized trials (3)
Denatured (35)
Depression (169)
Dermatology (68)
Diabetes (568)
Diagnostics (6794)
Digital health (46)
Diversity (11)
Diversity, equity & inclusion (40)
Drug discovery (313)
Drug pricing (231)
Drug shortages (38)
Duchenne muscular dystrophy (276)
Earnings (72725)
Editorial (71)
Employer branding (19)
Employer resources (141)
Events (99946)
Executive appointments (1114)
FDA (19023)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (32)
Funding (1572)
Gene editing (214)
Generative AI (61)
Gene therapy (707)
GLP-1 (1152)
Government (4866)
Grass and pollen (8)
Guidances (403)
Healthcare (17442)
HIV (79)
Huntington's disease (55)
IgA nephropathy (96)
Immunology and inflammation (313)
Immuno-oncology (90)
Indications (161)
Infectious disease (3127)
Inflammatory bowel disease (205)
Inflation Reduction Act (14)
Influenza (132)
Intellectual property (271)
Interviews (536)
IPO (14687)
IRA (57)
Job creations (3705)
Job search strategy (1788)
JPM (70)
Kidney cancer (21)
Labor market (81)
Layoffs (595)
Leadership (47)
Legal (7548)
Liver cancer (99)
Longevity (25)
Lung cancer (768)
Lymphoma (416)
Machine learning (51)
Management (55)
Manufacturing (971)
MASH (197)
Medical device (11744)
Medtech (11817)
Mergers & acquisitions (19569)
Metabolic disorders (1550)
mRNA (194)
Multiple sclerosis (184)
NASH (24)
Neurodegenerative disease (410)
Neuropsychiatric disorders (116)
Neuroscience (3315)
Neurotech (1)
NextGen: Class of 2026 (6162)
Non-profit (4272)
Now hiring (69)
Obesity (758)
Opinion (336)
Ovarian cancer (207)
Pain (253)
Pancreatic cancer (275)
Parkinson's disease (357)
Partnered (34)
Patents (559)
Patient recruitment (628)
Peanut (58)
People (59373)
Pharmaceutical (77)
Pharmacy benefit managers (36)
Phase 1 (21651)
Phase 2 (30719)
Phase 3 (23248)
Pipeline (7575)
Policy (346)
Postmarket research (2615)
Preclinical (9086)
Press Release (62)
Prostate cancer (284)
Psychedelics (62)
Radiopharmaceuticals (304)
Rare diseases (1061)
Real estate (5726)
Recruiting (65)
Regulatory (25086)
Reports (37)
Research institute (2448)
Resumes & cover letters (387)
Rett syndrome (33)
RNA editing (20)
RSV (88)
Schizophrenia (183)
Series A (259)
Series B (190)
Service/supplier (10)
Sickle cell disease (113)
Special edition (29)
Spinal muscular atrophy (171)
Sponsored (45)
Startups (3380)
State (2)
Stomach cancer (20)
Supply chain (127)
Tariffs (101)
The Weekly (111)
Vaccines (1088)
Venture capital (107)
Weight loss (520)
Women's health (100)
Worklife (23)
Date
Last 7 days (727)
Last 30 days (2395)
Last 365 days (28836)
2026 (9359)
2025 (28901)
2024 (33342)
2023 (37465)
2022 (48276)
2021 (52318)
2020 (51131)
2019 (44210)
2018 (33545)
2017 (31212)
2016 (30318)
2015 (35091)
2014 (28209)
2013 (23749)
2012 (25237)
2011 (26105)
2010 (23743)
Location
Africa (863)
Alabama (87)
Alaska (5)
Arizona (268)
Arkansas (15)
Asia (42347)
Australia (7719)
California (11259)
Canada (3565)
China (1290)
Colorado (514)
Connecticut (462)
Delaware (360)
Europe (92539)
Florida (1799)
Georgia (353)
Hawaii (2)
Idaho (54)
Illinois (959)
India (90)
Indiana (530)
Iowa (21)
Japan (519)
Kansas (117)
Kentucky (46)
Louisiana (37)
Maine (72)
Maryland (1447)
Massachusetts (8035)
Michigan (317)
Minnesota (620)
Mississippi (6)
Missouri (137)
Montana (32)
Nebraska (28)
Nevada (134)
New Hampshire (82)
New Jersey (3252)
New Mexico (28)
New York (3098)
North Carolina (1522)
North Dakota (6)
Northern California (5550)
Ohio (350)
Oklahoma (17)
Oregon (42)
Pennsylvania (2334)
Puerto Rico (29)
Rhode Island (47)
South America (1195)
South Carolina (81)
South Dakota (2)
Southern California (4495)
Tennessee (188)
Texas (1878)
United States (40876)
Utah (357)
Vermont (1)
Virginia (299)
Washington D.C. (77)
Washington State (954)
West Virginia (4)
Wisconsin (116)
Wyoming (2)
670,782 Results for "juniper pharma formerly known as columbia laboratories".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome
April 15, 2026
·
3 min read
Press Releases
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
April 10, 2026
·
5 min read
Government
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
The pharma industry “own Congress, they own the media,” Health Secretary Robert F. Kennedy, Jr. told lawmakers by way of explaining the bad press against FDA Commissioner Marty Makary following the second rejection of Replimune’s advanced melanoma drug.
April 17, 2026
·
2 min read
·
Tristan Manalac
Earnings
On steadier ground, pharma heads into Q1 earnings with deals top of mind
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trump’s new tariffs.
April 14, 2026
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions
Drug candidates don’t usually move among Big Pharma, but these five biotechs helped facilitate such hand-offs, scooping up assets from one pharma on the cheap before being bought out for billions by another.
November 19, 2025
·
9 min read
·
Tristan Manalac
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with Trump’s Most Favored Nation policy, patients will suffer.
April 2, 2026
·
3 min read
·
Annalee Armstrong
Patents
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
February 18, 2026
·
4 min read
·
Shawna Williams
Mergers & acquisitions
In Tight Deal Environment, Pharma May Need To Think Big
The major pharmas are loaded up with trillions in firepower—but are sticking to mid-cap deals. One expert says it might be time to think outside the box and shake up the industry with some consolidation.
March 18, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Vistin Pharma ASA: First quarter 2026 financial results
April 24, 2026
·
1 min read
Mergers & acquisitions
Pharma Double-Dippers Lead Q1 Deal Activity to Nearly $47B
Deal-hungry Big Pharmas, a long-sought biotech prize, an infrequent buyer and one serial biotech rabblerouser highlight a busy quarter in biopharma M&A.
April 1, 2026
·
1 min read
·
Annalee Armstrong
1 of 67,079
Next
